KKR is out of Integer Holdings entirely, unloading its remaining stake at $127 a share and closing out a cash-settled swap position alongside it. The holder now owns zero.
Latest Activity
Integer missed on both lines, with adjusted EPS falling well short of expectations as electrophysiology product headwinds and costs tied to the pending $5.7 billion KKR buyout piled up. There is no outlook and no conference call, so the deal closing by year-end is the only story left for holders.
KKR now sits on more than 10% of a $4.3 billion medical device manufacturer, and that stake comes with a say in how this company gets run. Private equity rarely takes a position this size without a plan for it.